Raymond James Financial Services Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $8.72M | Buy |
8,297
+253
| +3% | +$282K | 0.01% | 928 |
|
|
2024
Q2 | $8.45M | Sell |
8,044
-613
| -7% | -$594K | 0.01% | 902 |
|
|
2024
Q1 | $8.33M | Sell |
8,657
-115
| -1% | -$109K | 0.01% | 896 |
|
|
2023
Q4 | $7.7M | Buy |
8,772
+381
| +5% | +$314K | 0.01% | 877 |
|
|
2023
Q3 | $6.91M | Buy |
8,391
+42
| +0.5% | +$33K | 0.01% | 869 |
|
|
2023
Q2 | $6M | Sell |
8,349
-31
| -0.4% | -$23.9K | 0.01% | 929 |
|
|
2023
Q1 | $6.89M | Sell |
8,380
-1,658
| -17% | -$1.25M | 0.01% | 855 |
|
|
2022
Q4 | $7.24M | Sell |
10,038
-439
| -4% | -$324K | 0.01% | 796 |
|
|
2022
Q3 | $7.22M | Sell |
10,477
-1,348
| -11% | -$848K | 0.02% | 757 |
|
|
2022
Q2 | $6.99M | Sell |
11,825
-1,108
| -9% | -$720K | 0.02% | 771 |
|
|
2022
Q1 | $9.03M | Sell |
12,933
-4,842
| -27% | -$3.06M | 0.02% | 734 |
|
|
2021
Q4 | $11.2M | Buy |
17,775
+2,308
| +15% | +$1.42M | 0.02% | 631 |
|
|
2021
Q3 | $9.36M | Sell |
15,467
-316
| -2% | -$196K | 0.02% | 684 |
|
|
2021
Q2 | $8.81M | Buy |
15,783
+1,990
| +14% | +$1.01M | 0.02% | 709 |
|
|
2021
Q1 | $6.53M | Buy |
13,793
+4,235
| +44% | +$2.06M | 0.01% | 779 |
|
|
2020
Q4 | $4.62M | Buy |
9,558
+159
| +2% | +$85.8K | 0.01% | 863 |
|
|
2020
Q3 | $5.26M | Sell |
9,399
-7,277
| -44% | -$4.41M | 0.02% | 739 |
|
|
2020
Q2 | $10.4M | Buy |
16,676
+7,891
| +90% | +$4.48M | 0.03% | 452 |
|
|
2020
Q1 | $4.29M | Buy |
8,785
+1,046
| +14% | +$431K | 0.02% | 580 |
|
|
2019
Q4 | $2.91M | Buy |
7,739
+494
| +7% | +$166K | 0.01% | 983 |
|
|
2019
Q3 | $2.01M | Sell |
7,245
-334
| -4% | -$98.8K | 0.01% | 1104 |
|
|
2019
Q2 | $2.37M | Buy |
7,579
+2,782
| +58% | +$926K | 0.01% | 1008 |
|
|
2019
Q1 | $1.97M | Buy |
4,797
+703
| +17% | +$289K | 0.01% | 1077 |
|
|
2018
Q4 | $1.53M | Buy |
4,094
+762
| +23% | +$279K | 0.01% | 1046 |
|
|
2018
Q3 | $1.35M | Buy |
3,332
+188
| +6% | +$71.5K | 0.01% | 1293 |
|
|
2018
Q2 | $1.08M | Buy |
3,144
+141
| +5% | +$44.1K | 0.01% | 1365 |
|
|
2018
Q1 | $1.03M | Buy |
3,003
+236
| +9% | +$82.1K | 0.01% | 1282 |
|
|
2017
Q4 | $1.04M | Sell |
2,767
-84
| -3% | -$34K | 0.01% | 1277 |
|
|
2017
Q3 | $1.27M | Sell |
2,851
-361
| -11% | -$172K | 0.01% | 1148 |
|
|
2017
Q2 | $1.58M | Buy |
3,212
+378
| +13% | +$165K | 0.01% | 997 |
|
|
2017
Q1 | $1.1M | Sell |
2,834
-101
| -3% | -$37.4K | 0.01% | 1126 |
|
|
2016
Q4 | $1.08M | Sell |
2,935
-82
| -3% | -$31.2K | 0.01% | 1075 |
|
|
2016
Q3 | $1.21M | Sell |
3,017
-1,070
| -26% | -$429K | 0.01% | 995 |
|
|
2016
Q2 | $1.43M | Sell |
4,087
-947
| -19% | -$365K | 0.01% | 880 |
|
|
2016
Q1 | $1.81M | Buy |
+5,034
| New | +$2.07M | 0.02% | 667 |
|
Other funds holding REGN
Raymond James Financial Services Advisors's REGN Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 3.1% in Q3 2024, buying an estimated $282K and bringing the position to 8,297 shares worth $8.72M. The position accounts for 0.01% of the portfolio, ranked #928.
Raymond James Financial Services Advisors first reported a position in REGN in Q1 2016 and has held it in 35 quarters since. The position peaked at $11.2M in Q4 2021. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.
- Raymond James Financial Services Advisors held 8,297 shares of Regeneron Pharmaceuticals worth $8.72M as of Q3 2024.
- Raymond James Financial Services Advisors bought 253 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $282K.
- Regeneron Pharmaceuticals made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #928 holding.
- Raymond James Financial Services Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 35 quarters since.
- Raymond James Financial Services Advisors's Regeneron Pharmaceuticals position peaked at $11.2M in Q4 2021.
- 1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.